|
1
|
Thandra KC, Barsouk A, Saginala K, Padala
SA, Barsouk A and Rawla P: Epidemiology of non-Hodgkin's lymphoma.
Med Sci (Basel). 9:52021. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zanoni L, Bezzi D, Nanni C, Paccagnella A,
Farina A, Broccoli A, Casadei B, Zinzani PL and Fanti S: PET/CT in
non-Hodgkin lymphoma: An Update. Semin Nucl Med. 53:320–351. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Laurent C, Cook JR, Yoshino T,
Quintanilla-Martinez L and Jaffe ES: Follicular lymphoma and
marginal zone lymphoma: how many diseases? Virchows Arch.
482:149–162. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Alderuccio JP and Kahl BS: Current
treatments in marginal zone lymphoma. Oncology (Williston Park).
36:206–215. 2022.PubMed/NCBI
|
|
5
|
Iwamuro M, Tanaka T and Okada H: Review of
lymphoma in the duodenum: An update of diagnosis and management.
Virchows Arch. 29:1852–186. 2023.
|
|
6
|
Goodlad JR, Cerroni L and Swerdlow SH:
Recent advances in cutaneous lymphoma-implications for current and
future classifications. Virchows Arch. 482:281–298. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Olsen EA, Whittaker S, Willemze R,
Pinter-Brown L, Foss F, Geskin L, Schwartz L, Horwitz S, Guitart J,
Zic J, et al: Primary cutaneous lymphoma: recommendations for
clinical trial design and staging update from the ISCL, USCLC, and
EORTC. Blood. 140:419–437. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bender JD, Rubinstein JD, Mizukawa B,
Perentesis JP and Pommert L: Use of gemcitabine, oxaliplatin, and
anti-CD20 therapy in children and adolescents with non-Hodgkin
lymphoma unfit for intensive therapy. Pediatr Blood Cancer.
70:e302142023. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tian XP, Cai J, Xia Y, Zhang YC, Wang L,
Liu PP, Huang HQ, Li YJ, Zhou H, Li ZM, et al: First-line
sintilimab with pegaspargase, gemcitabine, and oxaliplatin in
advanced extranodal natural killer/T cell lymphoma (SPIRIT): A
multicentre, single-arm, phase 2 trial. Lancet Haematol.
11:e336–e344. 2024. View Article : Google Scholar
|
|
10
|
St-Pierre F and Gordon LI: CAR T-cell
therapy for relapsed/refractory non-Hodgkin's lymphoma: A
comprehensive review. Clin Adv Hematol Oncol. 20:309–318. 2022.
|
|
11
|
Alnasser SM, Alharbi KS, Almutairy AF,
Almutairi SM and Alolayan AM: Autologous stem cell transplant in
Hodgkin's and Non-Hodgkin's lymphoma, multiple myeloma, and AL
amyloidosis. Cells. 12:28552023. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kelley RK, Ueno M, Yoo C, Finn RS, Furuse
J, Ren Z, Yau T, Klümpen HJ, Chan SL, Ozaka M, et al: Pembrolizumab
in combination with gemcitabine and cisplatin compared with
gemcitabine and cisplatin alone for patients with advanced biliary
tract cancer (KEYNOTE-966): A randomised, double-blind,
placebo-controlled, phase 3 trial. Lancet. 401:1853–1865. 2023.
View Article : Google Scholar
|
|
13
|
Gravett AM, Dalgleish AG and Copier J: In
vitro culture with gemcitabine augments death receptor and NKG2D
ligand expression on tumour cells. Sci Rep. 9:15442019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
van der Heijden MS, Sonpavde G, Powles T,
Necchi A, Burotto M, Schenker M, Sade JP, Bamias A, Beuzeboc P,
Bedke J, et al: Nivolumab plus gemcitabine-cisplatin in advanced
urothelial carcinoma. N Engl J Med. 389:1778–1789. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wu J, Zhou Y, Li Q, Zhang J and Mao Y:
Primary biliary non-Hodgkin's lymphoma: A case report. Medicine
(Baltimore). 100:e261102021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gante J, Georg S, Robez JG, Dubuc A and
Lauwers F: Primary extra-nodal non-Hodgkin's lymphoma affecting
mandibular bone: A case report. Pan Afr Med J. 41:2312022.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cheson BD, Fisher RI, Barrington SF,
Cavalli F, Schwartz LH, Zucca E, Lister TA; Alliance, Australasian
Leukaemia; Lymphoma Group and Eastern Cooperative Oncology Group;
European Mantle Cell Lymphoma Consortium;, ; et al: Recommendations
for initial evaluation, staging, and response assessment of Hodgkin
and non-Hodgkin lymphoma: The Lugano classification. J Clin Oncol.
32:3059–3068. 2014. View Article : Google Scholar
|
|
18
|
Argumánez Tello V, Sánchez-Montes C,
Mínguez Sabater A, Bauza M and Bustamante-Balén M: Diagnosis of
non-Hodgkin's lymphoma due to a tiny polyp in the cecum. Rev Esp
Enferm Dig. 115:732–733. 2023.
|
|
19
|
Zheng Q, Xie Y, Xu L, Chen D, Wu J, Liu S,
Wu L, Fang P and Xie F: LDHA as a predictive biomarker and its
association with the infiltration of immune cells in pancreatic
adenocarcinoma. J Gastrointest Oncol. 15:1746–1759. 2024.
View Article : Google Scholar
|
|
20
|
Tas F, Yasasever CT, Karabulut S, Tastekin
D and Duranyildiz D: Serum transforming growth factor-beta1 levels
may have predictive and prognostic roles in patients with gastric
cancer. Tumour Biol. 36:2097–2103. 2015. View Article : Google Scholar
|
|
21
|
Lin WH and Wu MN: Non-Hodgkin's lymphoma
with intraspinal involvement mimics bilateral thoracolumbar
plexopath. Acta Neurol Taiwan. 32:122–126. 2023.
|
|
22
|
Kassar O, Kahla AB, Koubaa A, Kallel F,
Amor IB and Elloumi M: Non-Hodgkin's lymphoma developed during
imatinib mesylate treatment of chronic myeloid leukemia. J Oncol
Pharm Pract. 29:996–998. 2023. View Article : Google Scholar
|
|
23
|
Jariwal R, Raza N, Bhandohal J and Cobos
E: Non-Hodgkin's plasmablastic lymphoma as initial presentation of
human immunodeficiency virus. J Investig Med High Impact Case Rep.
9:232470962110146892021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang Y, Liu X, Yan P, Bi Y, Liu Y and
Zhang ZJ: Association between type 1 and type 2 diabetes and risk
of non-Hodgkin's lymphoma: A meta-analysis of cohort studies.
Diabetes Metab. 46:8–19. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cazelles C, Belhadj K, Vellemans H, Camus
V, Poullot E, Gaulard P, Veresezan L, Itti E, Becker S, Carvalho M,
et al: Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in
refractory/relapsed diffuse large B-cell lymphoma: A real-life
study in patients ineligible for autologous stem-cell
transplantation. Leuk Lymphoma. 62:2161–2168. 2021. View Article : Google Scholar
|
|
26
|
Cui S, Huang J, Wei D, Yu L and Jiang S:
Oxaliplatin inhibits the EGFR-MAPK pathway to promote apoptosis in
HCT116 cells. Chin Pharmacol Bull. 38:1279–1280. 2022.
|
|
27
|
Zhang Z, Yu H, Yao W, Zhu N, Miao R, Liu
Z, Song X, Xue C, Cai C, Cheng M, et al: RRP9 promotes gemcitabine
resistance in pancreatic cancer via activating AKT signaling
pathway. Cell Commun Signal. 20:1882022. View Article : Google Scholar
|
|
28
|
Qu C, Ping N, Kong D, Liu A, Liu H, Xu T,
Xia F, Wu D and Jin Z: Dual epigenetic agents plus
rituximab-gemcitabine-oxaliplatin as salvage treatment in
relapsed/refractory diffuse large B-cell lymphoma patients failure
of salvage chemotherapy. Hematol Oncol. 40:914–921. 2022.
View Article : Google Scholar
|
|
29
|
Roider T, Wang X, Hüttl K, Müller-Tidow C,
Klapper W, Rosenwald A, Stewart JP, de Castro DG, Dreger P, Hermine
O, et al: The impact of SAMHD1 expression and mutation status in
mantle cell lymphoma: An analysis of the MCL Younger and Elderly
trial. Int J Cancer. 148:150–160. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Galleze A, Raache R, Cherif N, Eddaikra A,
Belhani M, Bensenouci A, Touil-Boukoffa C and Abbadi MC: Increased
level of lactate dehydrogenase correlates with disease growth in
Algerian children with lymphoma. J Hematol Oncol Res. 2:7–15. 2017.
View Article : Google Scholar
|
|
31
|
Xue VW, Chung JY, Córdoba CAG, Cheung AH,
Kang W, Lam EW, Leung KT, To KF, Lan HY and Tang PM: Transforming
growth factor-β: A multifunctional regulator of cancer immunity.
Cancers (Basel). 12:30992020. View Article : Google Scholar : PubMed/NCBI
|
